Glenmark Pharma continues to outperform industry growth rates. The company has recorded a 31% growth in topline. Profit before tax registered a growth of 54%, on the back of sharp rise in operating margins. Depreciation and Interest showed a sharp spurt however, on account of commissioning of its new Goa facility. The company has also performed impressively on the export front.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares (eoy) (m)
Diluted Earnings per share*
P/E (at current price)
To strengthen its position in the dermatology and respiratory segments, the company had acquired three large brands of Lyka Laboratories last year for a consideration of Rs 345 m. These include Alex (cough preparation), Flucort (dermatology steroid) and Sensur (pain balm). All the three brands have performed well during the year. The company is consicously reducing its dependence on the dermatology segment by launching products across various therapeutic segment. Some of the company's products launched in the anti-diabetes and cardiovascular segment seem to be doing well.
R&D efforts of the company also seem to be progressing well. The research activities of the company are focused in the areas of diabetes, asthma and pain management.Two molecules of the company are in advanced pre-clinical trial stage.
It seems that the company is taking all the right steps to maintain its growth trajectory in future. However, while growth in the domestic market is hard to come, the company is a bit late in cashing on the generic opportunity as it lacks an ANDA (Abbreviated New Drug Application) pipeline. In the domestic market on the other hand, the company faces stiff competition and it would be hard to maintain premium pricing going forward. Considering other peer valuations and a P/E multiple of 12x 9 months annualised earnings, the stock looks fairly valued at the current market price of Rs 255.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407